This page shows you your search results in order of relevance. This is page number 10.
Order by Relevance | Date
Total 969764 results found since Jan 2013.
Binocular Low-Contrast Letter Acuity and the Symbol Digit Modalities Test Improve the Ability of the Multiple Sclerosis Functional Composite to Predict Disease in Pediatric Multiple Sclerosis
Conclusions A modified MSFC (25FTW, 9HPT, SMDT, and binocular 1.25% LCLA) is more sensitive than the traditional MSFC or its components to capture the subtle impairments that characterize pediatric MS and should be validated in order to be considered for future pediatric MS trials.
Source: Multiple Sclerosis and Related Disorders - August 25, 2016 Category: Neurology Source Type: research
Clinical characteristics of patients with multiple sclerosis enrolled in a new registry in Egypt
Conclusions This is the first documented MS registry from Egypt. The clinical characteristics of MS in Egypt was similar to other Arab countries and western countries. MS is more common among females in Egypt, with RRMS being the most common presentation. Visual symptoms and motor symptoms were the most common presentations in RRMS and progressive MS, respectively. Our findings also highlight the value of establishing registries in Egypt in order to be able to study, prospectively, the clinical course of the disease, the response to various DMD's and the epidemiology of MS in Egypt.
Source: Multiple Sclerosis and Related Disorders - August 31, 2016 Category: Neurology Source Type: research
‘Clinic Speak’ Helps People With Multiple Sclerosis Take Control
The past couple of weeks have been exhausting for me, but at the same time, I’ve been rejuvenated with great information about living our lives with multiple sclerosis (MS).
Two weekends ago I was at MS Life 2016, an event in London for people with MS and their families, and this past weekend I attended two days of presentations (one for healthcare providers and the other for people living with MS) as part of MS Ireland’s annual patient conference.
The presenters at both of these events have given me mounds to digest regarding medical research, coping strategies, and advice on general well-being. I intend to share...
Source: Life with MS - September 27, 2016 Category: Neurology Authors: Trevis Gleason Tags: multiple sclerosis life with MS Living with MS multiple sclerosis clinical trials research Source Type: blogs
Multiple Sclerosis: association of gelatinase B/matrix metalloproteinase-9 with risk and clinical course the disease
Conclusion Although we did not find an association of this polymorphism with disease susceptibility or prognosis, MMP-9 appears to be a good therapeutic response marker for multiple sclerosis.
Source: Multiple Sclerosis and Related Disorders - December 12, 2016 Category: Neurology Source Type: research
Sexual Dysfunction Levels in Iranian Women Suffering from Multiple Sclerosis
Conclusion According to this study, sexual dysfunction, especially primary SD was one of the most prevalent problems among women with MS. In addition, this study showed a complex and multifactorial nature for SD among these women. In order to provide an appropriate treatment and management of SD, associated factors and their impacts should be considered.
Source: Multiple Sclerosis and Related Disorders - January 5, 2017 Category: Neurology Source Type: research
On Dark Days With Multiple Sclerosis, Sometimes a Rainbow Breaks Through
This week began the Celtic Spring season.
Before you look out at the snow banks or tell me that Punxsutawney Phil saw his shadow, so you’ve six more weeks of winter, this is an old tradition here in Ireland. For us, spring starts on the first of February with the Biddy’s Day celebrations, which have been modernized into the festival of St Brigid’s Day.
But whether you call it spring or winter, it’s still the season of cold wind and driving rain. But now and again, the sun’s long, low rays break through the clouds, even if it’s still raining. Ever since my first winter here, back in 2005, I’ve referred ...
Source: Life with MS - February 6, 2017 Category: Neurology Authors: Trevis Gleason Tags: multiple sclerosis awareness comments community life with MS ms community trevis gleason Source Type: blogs
Baseline Characteristics of Pediatric Patients with Multiple Sclerosis Enrolled in the PARADIGMS Study: A Randomized, Double-Blind Study of Fingolimod versus Interferon-{beta}-1a (P1.347)
Conclusions:Patients enrolled in the PARADIGMS study had a high frequency of relapses and Gd+ lesions early in their course of the disease and the majority were at post-pubertal stage. These characteristics are in line with the previously known pediatric MS cohorts. The recruitment target has been successfully met; however recruitment remains open to enroll additional eligible pre-pubertal patients.Study Supported by: Novartis Pharma AG.Disclosure: Dr. Chitnis received personal compensation for activities with Roche-Genentech and Sanofi-Genzyme. Dr. Chitnis received research support from EMD Serono, Biogen, Novartis and Ve...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Chitnis, T., Arnold, D., Banwell, B., Bruck, W., Ghezzi, A., Giovannoni, G., Greenberg, B., Krupp, L., Rostasy, K., Tardieu, M., Waubant, E., Wolinsky, J., Bar-Or, A., Stites, T., Jessop, N., Merschhemke, M. B., Gartner, J. Tags: Pediatric Multiple Sclerosis Source Type: research
Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in multiple sclerosis (P1.393)
Conclusions:Autoantibodies against the flotillin-1/2 heterocomplex, a peripheral membrane protein that is involved in axon outgrowth and regeneration of the optic nerve, seem to be specific for a small subset of patients with multiple sclerosis.Disclosure: Dr. Hahn has nothing to disclose. Dr. Trendelenburg has nothing to disclose. Dr. Scharf has nothing to disclose. Dr. Denno has nothing to disclose. Dr. Brakopp has nothing to disclose. Dr. Teegen has nothing to disclose. Dr. Probst has nothing to disclose. Dr. Wandinger has nothing to disclose. Dr. Buttmann has received personal compensation from Almirall Hermal GmbH for...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Hahn, S., Trendelenburg, G., Scharf, M., Denno, Y., Brakopp, S., Teegen, B., Probst, C., Wandinger, K.-P., Buttmann, M., Szabados, F., vom Dahl, M., Kumpfel, T., Eichhorn, P., Gold, H.-J., Paul, F., Jarius, S., Melzer, N., Stocker, W., Komorowski, L. Tags: Biomarkers and Experimental Studies for Multiple Sclerosis I Source Type: research
Localized over expression of FGF9 in the rat motor cortex reproduces the pathological features of grey matter lesions in progressive multiple sclerosis. (P2.364)
Conclusions:Increasing availability of FGF9 in the rat cortex results in demyelinated lesions that recapitulate the major pathological features associated with grey matter lesions in progressive multiple sclerosis. This observation combined with data demonstrating FGF9 expression is increased in patients identifies FGF9-dependent responses as a logical target for therapies designed to reduce accumulation of disability in patients with progressive disease.Study Supported by: Funding for this study was provided by the Hertie Foundation, Multiple Sclerosis Society and the Naomi Bramson Trust.Disclosure: Dr. Wrzos has nothing ...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Wrzos, C., McElroy, D., Thuemmler, K., Sebastian, S., Junker, A., Stadelmann-Nessler, C., Linington, C. Tags: Biomarkers and Experimental Studies for Multiple Sclerosis II Source Type: research
Intra Individual Variability in Reaction Time Is Sensitive Across the Lifespan in Multiple Sclerosis (P4.352)
Conclusions:IIV in reaction time tasks may be used as a sensitive measure of performance variability in patients with MS and is related to cognitive performance as well. IIV is impaired in MS across the lifespan, including pediatric patients. IIV is a novel and sensitive marker of cognitive involvement in patients with MS, and may predict future cognitive decline as in other diseases.Study Supported by: The Lourie Center for Pediatric Multiple Sclerosis, the Department of Defense, and the National Multiple Sclerosis Society.Disclosure: Dr. Pau has nothing to disclose. Dr. Shaw has nothing to disclose. Dr. Patel has nothing...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Pau, W., Shaw, M., Patel, R., Kasschau, M., Song, G., Krupp, L., Charvet, L. Tags: Cognitive Impairment in Multiple Sclerosis: Clinical and MRI Correlates Source Type: research
Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Primary Progressive Multiple Sclerosis in the ORATORIO Trial (P4.384)
Conclusions:In the ORATORIO trial, ocrelizumab increased by approximately 3-fold the proportion of patients with NEPAD vs placebo, as measured by the combination of no evidence of progression, no relapse and no MRI activity. NEPAD may represent a useful composite outcome to assess the absence of clinical and MRI features of disease progression and activity in patients with PPMS.Study Supported by:Sponsored by F. Hoffmann-La Roche Ltd.Disclosure: Dr. Wolinsky has received personal compensation for activities with AbbVie, AcademicCME, Alkermes, Bayer HealthCare, Forward Pharma A/S, Novartis, Roche/Genentech, Sanofi Genzyme, ...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Wolinsky, J., Montalban, X., Kappos, L., Hauser, S., Giovannoni, G., de Seze, J., Bar-Or, A., Masterman, D., Bernasconi, C., Wei, W., Garren, H., Chin, P., Belachew, S., Arnold, D. Tags: No Evidence of Disease Activity in Multiple Sclerosis Source Type: research
Efficacy of Ocrelizumab on Brain MRI Outcomes in Patients with Early Relapsing Multiple Sclerosis: Pooled Analysis of the OPERA Studies (P6.338)
Conclusions:Ocrelizumab reduced brain MRI lesion activity and the rate of brain volume loss vs IFNβ-1a in patients with early RMS.Study Supported by:Sponsored by F. Hoffmann-La Roche Ltd.Disclosure: Dr. Traboulsee has received personal compensation for activities with Genzyme and Roche as a consultant. Dr. Traboulsee has received research support from Genzyme, Roche, and Chugai. Dr. Hauser has received personal compensation for activities with Annexon, Symbiotix, Bionure as a scientific advisory board member and from F. Hoffmann-La Roche Ltd. Dr. Havrdova has received personal compensation for activities with Biogen, ...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Traboulsee, A., Hauser, S., Havrdova, E., Kappos, L., Racke, M., Selmaj, K., Belachew, S., Bernasconi, C., Buffels, R., Garren, H., Wei, W., Arnold, D. Tags: Disease Modifying Therapy for Multiple Sclerosis: Efficacy and Clinical Trial Outcomes I Source Type: research
The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis
Conclusions Higher total alcohol and red wine intake were associated with a lower cross-sectional level of neurologic disability in MS patients but increased T2LV accumulation. Further studies should explore a potential cause-effect neuroprotective relationship, as well as the underlying biological mechanisms.
Source: Multiple Sclerosis and Related Disorders - July 7, 2017 Category: Neurology Source Type: research
Infectious mononucleosis and multiple sclerosis – Updated review on associated risk
Discussion Overall, new literature on IM and risk of MS categorically supports the association. Future work should focus on other risk factors such as age and gender on IM and subsequent risk of MS.
Source: Multiple Sclerosis and Related Disorders - July 7, 2017 Category: Neurology Source Type: research
Hopeful Cord Blood Treatment for Multiple Sclerosis
Multiple Sclerosis (MS) is a disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body.
Our central nervous system is covered in myelin, a “fatty white substance” that surrounds and protects the nerve fibers that are responsible for transmitting information to the brain, spinal cord, and the rest of the body. Multiple sclerosis attacks and destroys the myelin and as these nerve cells deteriorate, symptoms of MS such as “numbness, loss of vision, fatigue and tremors” start to occur.
There are different phases or “courses” of MS most oft...
Source: Cord Blood News - July 24, 2017 Category: Perinatology & Neonatology Authors: Maze Cord Blood Tags: Cord Blood medical research stem cells multiple sclerosis Source Type: blogs
